透析液钾3.0联合环硅酸锆钠对高钾血症血透患者心律失常的影响
本研究纳入维持性血透合并高钾血症成人患者,随机交叉比较透析液钾2.0 mmol/L不加环硅酸锆钠(SZC)与透析液钾3.0 mmol/L联合非透析日SZC两种策略。结果发现3.0钾/SZC组心房颤动(AF)发生率、临床显著心律失常发生率及透析后低钾血症均低于2.0钾/noSZC组。
要点
- 透析液钾3.0联合SZC较2.0不加SZC降低AF发生率(9.7 vs 13.4/人年)。
- 联合策略还减少临床显著心律失常和透析后低钾血症。
- 联合策略使血钾更多处于4.0-5.5 mmol/L目标窗内。
核心结论
- 在高钾血症维持性血透患者中,透析液钾3.0 mmol/L联合非透析日SZC相比透析液钾2.0 mmol/L不加SZC可降低AF、其他临床显著心律失常及透析后低钾血症发生率。
研究设计与样本
- 随机交叉试验,纳入透析≥3个月且透析前血钾5.1-6.5 mmol/L的成人88例,平均年龄57.1岁,51%男性,平均透析前血钾5.5 mmol/L,随访25.5人年。
主要发现
- 9例患者共检出296次AF发作;3.0钾/SZC组未调整AF发生率为9.7/人年,2.0钾/noSZC组为13.4/人年(模型率比0.52;95%CI 0.41-0.65)。
- 临床显著心律失常发生率3.0钾/SZC组为6.8/人年,2.0钾/noSZC组为10.2/人年(模型率比0.47;95%CI 0.38-0.58)。
- 血钾测量值超出最佳窗(4.0-5.5 mmol/L)的模型比值比为0.27(95%CI 0.12-0.35), favoring 3.0钾/SZC组。
- 低钾血症发生例数3.0钾/SZC组为33例,2.0钾/noSZC组为58例。
关键数值与推荐
- 透析前血钾入选范围5.1-6.5 mmol/L;目标透析前血钾4.0-5.5 mmol/L;AF发作判定标准为持续时间至少2分钟。
临床怎么用
- 对于维持性血透合并高钾血症患者,可考虑采用透析液钾3.0 mmol/L联合非透析日SZC以降低AF及临床显著心律失常风险,并减少透析后低钾血症。
局限性
- 样本量较小(88例),AF事件集中于9例患者;研究为交叉设计,随访时间有限(25.5人年)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The optimal approach towards managing serum potassium (sK+) and hemodialysate potassium concentrations is uncertain. To study this, adults receiving hemodialysis for three months or more with hyperkalemia (pre-dialysis sK+ 5.1-6.5 mmol/l) had cardiac monitors implanted and were randomized to either eight weeks of 2.0 mmol/l potassium/1.25 mmol/l calcium dialysate without sodium zirconium cyclosilicate (SZC) (2.0 potassium/noSZC) or 3.0 mmol/l potassium/1.25 mmol/l calcium dialysate combined with SZC (3.0 potassium/SZC) on non-dialysis days to maintain pre-dialysis sK+ 4.0-5.5 mmol/l, followed by treatment crossover for another eight weeks. The primary outcome was the rate of adjudicated atrial fibrillation (AF) episodes of at least 2 minutes duration. Secondary outcomes included clinically significant arrhythmias (bradycardia, ventricular tachycardia, and/or asystole) and the proportion of sK+ measurements within an optimal window of 4.0-5.5 mmol/l. Among 88 participants (mean age: 57.1 years; 51% male; mean pre-dialysis sK+: 5.5 mmol/l) with 25.5 person-years of follow-up, 296 AF episodes were detected in nine patients. The unadjusted AF rate was lower with 3.0 potassium/SZC versus 2.0 potassium/noSZC; 9.7 vs. 13.4/person-year (modeled rate ratio 0.52; 95% confidence interval 0.41-0.65). Clinically significant arrhythmias were reduced with 3.0 potassium/SZC vs. 2.0 potassium/noSZC (6.8 vs. 10.2/person-year modeled rate ratio 0.47; 0.38; 0.58). Fewer sK+ measurements outside the optimal window occurred with 3.0 potassium/SZC (modeled odds ratio: 0.27; 0.12-0.35). Hypokalemia was less frequent (33 vs. 58 patients) with 3.0 potassium/SZC compared with 2.0 potassium/noSZC. Thus, in patients with hyperkalemia on maintenance hemodialysis, a combination of hemodialysate potassium 3.0 mmol/l and SZC on non-hemodialysis days reduced the rates of AF, other clinically significant arrhythmias, and post-dialysis hypokalemia compared with hemodialysate potassium 2.0/noSZC.
引用
- Charytan DM, Winkelmayer WC, Granger CB, et al. Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia. Kidney Int. 2024. PMID: 39490411. doi:10.1016/j.kint.2024.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。